Galmed Pharmaceuticals Ltd (NASDAQ: GLMD)’s stock price has increased by 158.19 compared to its previous closing price of 3.87. However, the company has seen a 180.68% increase in its stock price over the last five trading sessions. investorplace.com reported 2024-04-10 that Now could be a great time for investors to consider stacking up on penny stocks. These companies often have significant growth potential.
Is It Worth Investing in Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) Right Now?
Additionally, the 36-month beta value for GLMD is 0.66. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GLMD is 0.62M and currently, short sellers hold a 1.94% ratio of that float. The average trading volume of GLMD on September 17, 2024 was 75.57K shares.
GLMD’s Market Performance
GLMD stock saw an increase of 180.68% in the past week, with a monthly gain of 197.38% and a quarterly increase of 159.64%. The volatility ratio for the week is 15.64%, and the volatility levels for the last 30 days are 16.86% for Galmed Pharmaceuticals Ltd (GLMD). The simple moving average for the last 20 days is 178.28% for GLMD stock, with a simple moving average of 136.08% for the last 200 days.
Analysts’ Opinion of GLMD
Many brokerage firms have already submitted their reports for GLMD stocks, with B. Riley FBR repeating the rating for GLMD by listing it as a “Neutral.” The predicted price for GLMD in the upcoming period, according to B. Riley FBR is $8 based on the research report published on May 22, 2020 of the previous year 2020.
Craig Hallum, on the other hand, stated in their research note that they expect to see GLMD reach a price target of $18. The rating they have provided for GLMD stocks is “Buy” according to the report published on February 04th, 2020.
Cantor Fitzgerald gave a rating of “Overweight” to GLMD, setting the target price at $14 in the report published on January 30th of the previous year.
GLMD Trading at 177.71% from the 50-Day Moving Average
After a stumble in the market that brought GLMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.83% of loss for the given period.
Volatility was left at 16.86%, however, over the last 30 days, the volatility rate increased by 15.64%, as shares surge +115.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +123.52% upper at present.
During the last 5 trading sessions, GLMD rose by +119.10%, which changed the moving average for the period of 200-days by +85.71% in comparison to the 20-day moving average, which settled at $3.80. In addition, Galmed Pharmaceuticals Ltd saw 83.01% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for GLMD
The total capital return value is set at -0.53. Equity return is now at value -52.67, with -44.20 for asset returns.
Currently, EBITDA for the company is -7.46 million with net debt to EBITDA at 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.48.
Conclusion
In conclusion, Galmed Pharmaceuticals Ltd (GLMD) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
